Oral Tirzepatide vs Orforglipron (Foundayo)
This comparison would not have made sense a year ago. Now it is one of the more useful ones on the site, because the two products sit at opposite ends of a trade-off: the strongest GLP-1 molecule in a form nobody has tested, or a weaker molecule in the first pill that behaves like a normal pill.
The oral tirzepatide page covers our compounded capsule and its honest limits. This page puts it next to the approved alternative.
Orforglipron: the first GLP-1 pill without a ritual
Approved by the FDA on April 1 2026 under the brand name Foundayo, orforglipron is a different kind of GLP-1 drug. Semaglutide and tirzepatide are peptides — chains of amino acids that the stomach digests, which is why they are injected or, as tablets, need chemical protection and an empty stomach. Orforglipron is a small molecule, not a peptide. It survives digestion on its own, so it can be taken at any time of day, with or without food, with no wait afterwards.
In ATTAIN-1 — 3,127 adults with obesity or overweight, 72 weeks — participants on the highest strength lost 12.4% of their body weight against 0.9% on placebo, with improvements in waist circumference, non-HDL cholesterol, triglycerides and blood pressure. Side effects were the class's usual gastrointestinal ones, plus — unusually for the class — hair loss appearing on the label's common-effects list.
Its weight-loss effect is smaller than injectable semaglutide's and considerably smaller than injectable tirzepatide's. It is also the only GLP-1 pill that asks nothing of your morning.
Compounded oral tirzepatide: the stronger molecule, untested route
Tirzepatide is the more powerful drug — dual GIP and GLP-1 action, 20% or more weight loss in the injectable trials. But there is no approved oral tirzepatide, and Lilly has not announced one. Every oral tirzepatide on the market is compounded: the peptide in a capsule, with an absorption enhancer chosen by the pharmacy, at a strength chosen by the prescriber.
What that means is set out on the main page: the molecule's evidence is borrowed from the injectable trials, and the absorbed fraction is unknown and probably variable. It is the same shape of uncertainty as compounded oral semaglutide, with less to borrow from, because tirzepatide has never had an approved oral formulation of any kind to compare against.
The regulatory position is also narrower after the FDA's 2026 actions on compounded GLP-1s, covered on the compounded tirzepatide page.
Putting them side by side
| Orforglipron (Foundayo) | Compounded oral tirzepatide | |
|---|---|---|
| Molecule | Small-molecule GLP-1 agonist | Peptide GIP/GLP-1 dual agonist |
| Approval | FDA-approved, April 2026 | Not approved; compounded only |
| Trial evidence for the pill | 72-week phase 3, 3,127 participants | None |
| Weight loss (trial) | ~12% at 72 weeks | Unknown for the capsule |
| Food and timing rules | None | Empty stomach; pharmacy-specific |
| Insurance | Covered by some plans; in the Medicare Bridge program | Not covered |
| Predictability | High | Low to moderate |
How we think about the choice
If the goal is a pill, and a modest-to-good result with high predictability is acceptable, orforglipron is the first oral GLP-1 we can recommend without caveats about absorption. It suits the patient who has tried to keep to the empty-stomach routine of the semaglutide tablets and could not, and the patient for whom a dozen percent is the right amount of weight to lose.
If the goal is the larger effect that tirzepatide produces, the honest route to it is the injection. A compounded oral capsule is an attempt to have both the stronger molecule and the pill, and the price of the attempt is not knowing how much of the drug you are getting. We carry it because some patients, fully informed, choose that trade. We do not present it as equivalent to either the injection or the approved pill.
Frequently asked questions
No. Every oral tirzepatide is compounded. Orforglipron is a different molecule and the only oral GLP-1 approved for weight loss that has no food or water restrictions.
Orforglipron has a 72-week trial showing about 12% weight loss. Compounded oral tirzepatide has no trial, so the question cannot be answered — the injectable tirzepatide data does not transfer to a capsule with unknown absorption.
It is not a peptide, so digestion does not destroy it. Semaglutide tablets are peptides that need an absorption enhancer and an empty stomach.
Hair loss appears on its list of common side effects, which is unusual for the class. It is generally attributed to rapid weight loss rather than the drug itself, but it is on the label.
No. Combining GLP-1 medications is specifically warned against.
Coverage varies by plan. It is one of three products included in the Medicare GLP-1 Bridge program from July 2026 — see Medicare and GLP-1s.
Where this fits in your plan
The Tirzepatide Oral Capsules page covers our product; the Tirzepatide Injection page covers the route with the evidence. A baseline panel comes first either way.
We measure first. Then we act.
References
- Eli Lilly. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1 2026.
- ATTAIN-1: orforglipron in adults with obesity or overweight — phase 3 results. NEJM 2025.
- Foundayo (orforglipron) prescribing information, April 2026.
- FDA. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. April 30 2026.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022;387:205–216.
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
All medical decisions are made solely by licensed healthcare professionals. Medications are prescribed only when medically necessary. GLP-1 medications are not suitable for everyone. Results may vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.